1. Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

2. This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. The abstract data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. Case: A 74-Year-Old Man With a History of Noninvasive Bladder Cancer

5. Discussion With Patient

6. Criteria that Render Patients Ineligible for Cisplatin

7. Case (cont)

8. Ongoing Phase 3 Adjuvant Clinical Trials

9. Case (cont)

10. Treatment Options

11. NCCN Preferred Options

12. Updates to Use of Checkpoint Inhibition in the First-Line Setting

13. FDA Statement on Restrictions to Use

14. PD-L1 Testing

15. Outstanding Questions on PD-L1 Testing

16. Follow-Up With Patient

17. Case Conclusion

18. Predictive Biomarkers

19. Clinical Trials in the Neoadjuvant Setting

20. Clinical Trials in Non-Muscle Invasive Disease

21. Oncologist and Urologist Working Relationship

22. Immune Checkpoint Inhibitors in the Second-Line Setting

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)